Literature DB >> 8780171

Activation of human umbilical vein endothelial cell progelatinase A by phorbol myristate acetate: a protein kinase C-dependent mechanism involving a membrane-type matrix metalloproteinase.

H D Foda1, S George, C Conner, M Drews, D C Tompkins, S Zucker.   

Abstract

Matrix metalloproteinases play an important role in tumor invasion, angiogenesis and inflammatory tissue destruction. The 72-kd gelatinase A is the most widely distributed. Along with the 92-kd gelatinase B, it plays an important role in basement membrane turnover. Gelatinase A is secreted as progelatinase A and, when activated, can cause extracellular matrix destruction. The physiologic mechanism of this activation is not well understood. Based on the importance of endothelial cells in inflammation and cancer, we sought in this study to systematically study the PMA-induced activation of endothelial cell progelatinase A. Using HUVEC, we demonstrated that PMA-induced activation of progelatinase A in these vascular endothelial cells (a) was protein kinase C-dependent as it was blocked by H-7; (b) occurred through cell-mediated events as PMA was unable to activate progelatinase A in a cell-free system and that low dose tissue inhibitor of metalloproteinases-2, but not tissue inhibitor of metalloproteinases-1, totally inhibited PMA-induced activation; (c) was accompanied by an increase in the membrane-type matrix metalloproteinase (MT-MMP). We also found that the combination of PMA and the cytokine tumor necrosis factor-alpha increased HUVEC secretion and activation of gelatinase B. In conclusion, our data show that PMA activation of vascular endothelial cell progelatinase A is a cell membrane event that is at least partially mediated through a PKC-dependent mechanism and is accompanied by an increase synthesis of MT-MMP. These data suggest a role for MT-MMP in the activation of progelatinase A in vascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780171

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  11 in total

1.  Matrix metalloproteinases modulated by protein kinase Cε mediate resistin-induced migration of human coronary artery smooth muscle cells.

Authors:  Qinxue Ding; Hong Chai; Nausheen Mahmood; Jerry Tsao; Daria Mochly-Rosen; Wei Zhou
Journal:  J Vasc Surg       Date:  2011-01-31       Impact factor: 4.268

2.  Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species.

Authors:  M A Lafleur; M D Hollenberg; S J Atkinson; V Knäuper; G Murphy; D R Edwards
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

3.  Inostamycin, an inhibitor of cytidine 5'-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): inositol transferase, suppresses invasion ability by reducing productions of matrix metalloproteinase-2 and -9 and cell motility in HSC-4 tongue carcinoma cell line.

Authors:  Y Baba; M Tsukuda; I Mochimatsu; S Furukawa; H Kagata; N Sakai; S Koshika; M Imoto; Y Kato
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Tumorigenic potential of extracellular matrix metalloproteinase inducer.

Authors:  S Zucker; M Hymowitz; E E Rollo; R Mann; C E Conner; J Cao; H D Foda; D C Tompkins; B P Toole
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

5.  Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3.

Authors:  S Cowell; V Knäuper; M L Stewart; M P D'Ortho; H Stanton; R M Hembry; C López-Otín; J J Reynolds; G Murphy
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

6.  Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells.

Authors:  Hiromichi Nakabayashi; Toshio Yawata; Keiji Shimizu
Journal:  BMC Cancer       Date:  2010-06-29       Impact factor: 4.430

7.  Influence of VEGF-R2 inhibition on MMP secretion and motility of microvascular human cerebral endothelial cells (HCEC).

Authors:  Sven Wagner; Tim Fueller; Vera Hummel; Peter Rieckmann; Joerg-Christian Tonn
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

8.  Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach.

Authors:  Danmei Xu; Naoko Suenaga; Mariola J Edelmann; Rafael Fridman; Ruth J Muschel; Benedikt M Kessler
Journal:  Mol Cell Proteomics       Date:  2008-07-02       Impact factor: 5.911

9.  Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.

Authors:  P A Forsyth; H Wong; T D Laing; N B Rewcastle; D G Morris; H Muzik; K J Leco; R N Johnston; P M Brasher; G Sutherland; D R Edwards
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

10.  Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas.

Authors:  L L Groft; H Muzik; N B Rewcastle; R N Johnston; V Knäuper; M A Lafleur; P A Forsyth; D R Edwards
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.